ArticleNature communications2026
Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newly-diagnosed glioblastoma (nGBM) remains a significant unmet need with limited therapeutic options. Here, we present the results of a single-arm, open-label phase 1b trial on neoantigen-pulsed autologous dendritic cells (ZSNeo-DC) as an adjuvant treatment for nGBM. The primary endpoint was safety, as assessed by the incidence and severity of adverse events (AEs). Eleven patients with nGBM received intradermal administration of ZSNeo-DC following surgery and standard radio-chemotherapy. Treatment was well tolerated, with AEs predominantly grade 1 or 2; only two grade-1/2 febrile AEs were recorded as treatment-related. Secondary endpoint analysis showed that median progression-free survival (PFS) was 16.2 months, median overall survival (OS) was not reached, and 12-month OS rate was 100% from surgery. A range of 1.9- to 284.7-fold (median: 7.2-fold) and 0.7- to 507.0-fold (median: 10.3-fold) increase of peripheral neoantigen-specific immune response (NSIR) was observed respectively after the 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.